Dornase alfa – Cystic fibrosis – as per NHS England policy

NICE recommendations, summary of meeting discussions, links to additional supporting docs etc.

NNUH shared care protocol available – redesigned version supported by the TAG in September 2004.

March 2008: A revised version was developed by the NNUH  and approved by the TAG.

May 2008: The JPUH and the QEH agreed to adopt the shared care protcol.

September 2010: Version reviewed and approved by the TAG.

January 2013: Supported by the TAG for use until National Specialised Commissioning Group (NSCG) takes over commissioning responsibility with likely transfer to homecare providers during 2013. To be reviewed in 2014.

The Shared Care Protocol is available via the Knowledge Management website: http://nww.knowledgeanglia.nhs.uk/tag/tag_guidance.htm

March 2014: Shared Care Agreement reviewed and use extended until March 2015. Supported by the TAG and D&TCG.

March 2015:  The TAG was asked to review classification from Amber (Option for GP prescribing under an approved Shared Care Agreement) to Red since confirmation had been received that all local patients have been repatriated to specialist care under NHS England Specialised Commissioning arrangements. The shared care agreement could therefore be revoked.

The TAG confirmed that classification of Red (Hospital/Specialist only) should be recommended for Dornase Alfa in Cystic Fibrosis (CF).

March 2015:  The Norfolk & Waveney CCGs’ D&TCG noted and supported the TAG’s recommendation to re-classify Dornase Alfa for use in patients with cystic fibrosis to Red (Hospital/Specialist only).

November 2017:

The TAG acknowledged NICE NG 78 (October 2017) – Cystic fibrosis: diagnosis and management